X0202 SCHEDULE 13G 0001952142 XXXXXXXX LIVE Common stock, par value $0.00001 06/30/2026 0001279704 Cellectar Biosciences, Inc. 15117F880 100 Campus Drive Florham Park NJ 07932 Rule 13d-1(b) StemPoint Capital LP DE 0.00 779976.00 0.00 845740.00 845740.00 N 9.9 IA PN StemPoint Capital Management GP LLC DE 0.00 779976.00 0.00 845740.00 845740.00 N 9.9 OO StemPoint Capital Management GP LLC is a limited liability company. Michelle Ross X1 0.00 779976.00 0.00 845740.00 845740.00 N 9.9 HC IN Cellectar Biosciences, Inc. 100 Campus Drive, Florham Park, NJ 07932 This filing is being jointly filed by StemPoint Capital LP, StemPoint Capital Management GP LLC, and Michelle Ross (collectively, the "Reporting Persons" and each a "Reporting Person"). The business addresses of each Reporting Person is: 520 Madison Avenue, 19th Floor New York, NY 10022 StemPoint Capital LP is a limited partnership organized under the laws of the State of Delaware. StemPoint Capital Management GP LLC is a limited liability company organized under the laws of the State of Delaware. Michelle Ross is a citizen of the United States of America. N IA HC Items 5-9 of each cover page are incorporated by reference. Each Reporting Person may be deemed to be the beneficial owner of 845,740 shares of Common Stock, par value $0.00001 (the "Common Stock"), consisting of 354,938 shares of Common Stock and (ii) 490,802 shares of Common Stock through the exercise of a pre-funded warrant (the "Pre-Funded Warrants"). The Pre-Funded Warrants are subject to a beneficial ownership limitation of 9.99% (the "Beneficial Ownership Limitation"). Each Reporting Person may be deemed to beneficially own 9.99% shares of Common Stock, which is calculated based on (i) 7,975,069 shares of Common Stock reported as issued and outstanding as of June 2, 2026, in the Company's Prospectus Supplement filed with the Securities and Exchange Commission on June 2, 2026, plus 490,802 shares of Common Stock which may be acquired upon the exercise of the Pre-Funded Warrants, which are subject to the Beneficial Ownership Limitation, which amount has been added to the shares outstanding in accordance with Rule 13d-3(d)(1)(i) under the Act. The foregoing excludes 421,273 shares of Common Stock underlying the Pre-Funded Warrants, which is subject to the Beneficial Ownership Limitation. Due to field limitations of the EDGAR filing system, the percentages listed in Row 11 of the Reporting Persons' cover pages have been rounded down to 9.9%. -0- 779,976. Comment: Shared voting power includes 490,802 Warrants beneficially owned by the Reporting Persons. -0- 845,740. Comment: Shared dispositive power includes 490,802 Warrants beneficially owned by the Reporting Persons. Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) StemPoint Capital LP /s/ Sean C. Tan 08/14/2026 StemPoint Capital Management GP LLC /s/ Sean C. Tan 08/14/2026 Michelle Ross /s/ Michelle Ross 08/14/2026